Bone substitute compositions and method of use
First Claim
Patent Images
1. A bone cement composition consisting essentially of:
- a mineral component that hardens in an aqueous environment, wherein said mineral component is selected from the group consisting of calcium sulfate-anhydrous, calcium sulfate-dihydrate, calcium sulfate α
-hemihydrate, calcium sulfate β
-hemihydrate, and combinations thereof; and
a non-aqueous component having an aqueous replacement characteristic that causes the composition to harden to a crystalline state in vivo when the non-aqueous component is replaced with aqueous body fluid.
5 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to novel bone substitute compositions and methods of use. It further encompasses the use of these novel bone substitute compositions for bone augmentation and the treatment of disease conditions. The invention also contemplates a kit including bone substitute compositions and a percutaneous delivery device.
177 Citations
23 Claims
-
1. A bone cement composition consisting essentially of:
-
a mineral component that hardens in an aqueous environment, wherein said mineral component is selected from the group consisting of calcium sulfate-anhydrous, calcium sulfate-dihydrate, calcium sulfate α
-hemihydrate, calcium sulfate β
-hemihydrate, and combinations thereof; anda non-aqueous component having an aqueous replacement characteristic that causes the composition to harden to a crystalline state in vivo when the non-aqueous component is replaced with aqueous body fluid. - View Dependent Claims (2, 3, 4)
-
-
5. A bone cement composition consisting essentially of:
-
calcium sulfate-anhydrous; calcium sulfate-dihydrate; and polyethylene glycol (PEG), wherein said PEG is replaced with aqueous body fluid in situ to harden said composition to a crystalline state in vivo. - View Dependent Claims (6, 7, 8, 9, 10)
-
-
11. A bone cement composition consisting essentially of:
-
calcium sulfate-anhydrous; calcium sulfate α
-hemihydrate;calcium sulfate-dihydrate; and
ppolyethylene glycol (PEG), wherein said PEG is replaced with aqueous body fluid to harden said composition to a crystalline state in vivo. - View Dependent Claims (12)
-
-
13. A method comprising:
-
providing a composition consisting essentially of; a mineral component that hardens in an aqueous environment, wherein said mineral component is selected from the group consisting of calcium sulfate-anhydrous, calcium sulfate-dihydrate, calcium sulfate α
-hemihydrate, calcium sulfate β
-hemihydrate, and combinations thereof; anda non-aqueous component having an aqueous replacement characteristic that causes the composition to harden to a crystalline state when the non-aqueous component is replaced with aqueous body fluid; and delivering said composition to a bone, wherein said non-aqueous component is replaced with aqueous body fluid, thereby hardening said composition to a crystalline state in vivo to provide a hardened bone substitute material in contact with the bone. - View Dependent Claims (14, 15)
-
-
16. A method comprising:
-
providing a bone cement composition consisting essentially of a mineral component, wherein said mineral component is selected from the group consisting of calcium sulfate-anhydrous, calcium sulfate-dihydrate, calcium sulfate α
-hemihydrate, calcium sulfate β
-hemihydrate, and combinations thereof and a non-aqueous component having an aqueous replacement characteristic;inserting an expandable device into a bone; expanding said expandable device to create a cavity or space within the bone; and delivering said composition to the bone through a delivery device, wherein said non-aqueous component is replaced with aqueous body fluid, thereby hardening said composition to a crystalline state in vivo to provide a hardened bone substitute material.
-
-
17. A kit comprising:
-
a percutaneous delivery device; and a composition consisting essentially of; a mineral component that hardens in an aqueous environment, wherein said mineral component is selected from the group consisting of calcium sulfate-anhydrous, calcium sulfate-dihydrate, calcium sulfate α
-hemihydrate, calcium sulfate β
-hemihydrate, and combinations thereof; anda non-aqueous component having an aqueous replacement characteristic that causes the composition to harden to a crystalline state in vivo when the non-aqueous component is replaced with aqueous body fluid. - View Dependent Claims (18, 19, 20)
-
-
21. A method comprising:
-
providing the kit comprising;
a percutaneous delivery device, anda composition consisting essentially of a mineral component that hardens in an aqueous environment, wherein said mineral component is selected from the group consisting of calcium sulfate-anhydrous, calcium sulfate-dihydrate, calcium sulfate α
-hemihydrate, calcium sulfate β
-hemihydrate, and combinations thereof; anda non-aqueous component having an aqueous replacement characteristic that causes the composition to harden to a crystalline state when the non-aqueous component is replaced with aqueous body fluid, wherein said composition is ready for use; and delivering said composition to a bone, wherein the non-aqueous component is replaced with aqueous body fluid, thereby hardening said composition to a crystalline state in vivo to provide a hardened bone substitute material in contact with the bone.
-
-
22. A bone cement composition consisting essentially of:
-
a mineral component that hardens in an aqueous environment, wherein the mineral component consists essentially of calcium phosphate; and a non-aqueous component having an aqueous replacement characteristic that causes the composition to harden to a crystalline state in vivo when the non-aqueous component is replaced with aqueous body fluid, wherein the non-aqueous component is polyethylene glycol (PEG).
-
-
23. A bone cement composition consisting essentially of:
-
a mineral component that hardens in an aqueous environment, wherein the mineral component consists essentially of calcium aluminate; and a non-aqueous component having an aqueous replacement characteristic that causes the composition to harden to a crystalline state in vivo when the non-aqueous component is replaced with aqueous body fluid, wherein the non-aqueous component is polyethylene glycol (PEG).
-
Specification